Skip to content
Disclosery

Foresite Capital Management IV, LLC

Follow

13F filer, CIK 1704132, WEST HOLLYWOOD, CA

Foresite Capital Management IV, LLC reported $290,151,348 across 6 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-097103

Period
2026-06-30
Reported value
$290M
Holdings
6
Top 10 weight
100%
New
1
Sold out
3

Part of the filer group Foresite Capital Management VI LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CYTKadded+211,400$18M
CRNXnew+150,000$5.61M
RLAYadded+250,000$4.68M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELexited-800,399-$16.1M
ALECexited-3,887,200-$8.36M
MAZEexited-156,901-$4.68M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001104659-26-097103, largest first. % of portfolio is the value over $290,151,348, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,397,881 shares; 2024Q4: 4,397,881 shares; 2025Q1: 4,410,581 shares; 2025Q2: 4,410,581 shares; 2025Q3: 4,778,581 shares; 2025Q4: 4,778,581 shares; 2026Q1: 4,778,581 shares; 2026Q2: 4,778,581 shares 4,778,581$165M56.95%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 458,295 shares; 2025Q4: 458,295 shares; 2026Q1: 503,295 shares; 2026Q2: 714,695 shares 714,695$60.9M20.98%+211,400Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,943,682 shares; 2026Q2: 1,943,682 shares 1,943,682$25.4M8.74%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,000,000 shares; 2024Q4: 1,000,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,250,000 shares 1,250,000$23.4M8.06%+250,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares; 2026Q2: 160,000 shares 160,000$9.66M3.33%0Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares 150,000$5.61M1.93%newTimeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LYELLYELL IMMUNOPHARMA INC800,399$16.1Mshares
ALECALECTOR INC3,887,200$8.36Mshares
MAZEMAZE THERAPEUTICS INC156,901$4.68Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-097103 base2026-08-14acceptance time not in the bulk data set